Lymphocyte Recovery Is a Major Determinant of Outcome after Matched Unrelated Myeloablative Transplantation for Myelogenous Malignancies

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 9, 2009, Pages 1108-1115

  Le Blanc, Katarina ^a,b   Barrett, A John ^c   Schaffer, Marie ^a   Hägglund, Hans ^a,b   Ljungman, Per ^a,b   Ringdén, Olle ^a,b   Remberger, Mats ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Graft versus host disease (GVHD); Hematopoietic stem cell transplantation (HSCT); Lymphocytes; Relapse free survival (RFS)

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; T LYMPHOCYTE ANTIBODY; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; CD34 SELECTION; CHILD; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DONOR SELECTION; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; INFANT; LEUKEMIA RELAPSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; MYELOID LEUKEMIA; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OVERALL SURVIVAL; PROGNOSIS; SURGICAL MORTALITY; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CYTOKINES; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT, NEWBORN; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 68049105397     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.05.015     Document Type: Article

References (33)

1. Powles R., Singhal S., Treleaven J., Kulkarni S., Horton C., and Mehta J. Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation. Blood 91 (1998) 3481-3486
2. Kim D.H., Kim J.G., Sohn S.K., et al. Clinical impact of early absolute lymphocyte count after allogeneic stem cell transplantation. Br J Haematol 125 (2004) 217-224
3. Kumar S., Chen M.G., Gastineau D.A., et al. Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 28 (2001) 951-956
4. Lee K.H., Choi S.J., Lee J.H., et al. Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Haematologica 90 (2005) 939-948
5. Chakrabarti S., Brown J., Guttridge M., Pamphilon D.H., Lankester A., and Marks D.I. Early lymphocyte recovery is an important determinant of outcome following allogeneic transplantation with CD34+ selected graft and limited T-cell addback. Bone Marrow Transplant 32 (2003) 23-30
6. Savani B.N., Mielke S., Rezvani K., et al. Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation. Biol Blood Marrow Transplant 13 (2007) 1216-1223
7. Savani B.N., Mielke S., Adams S., et al. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia 21 (2007) 2145-2152
8. Jiang Y.Z., Barrett A.J., Goldman J.M., and Mavroudis D.A. Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation. Ann Hematol 74 (1997) 1-6
9. Sconocchia G., del Principe D., and Barrett A.J. Non-classical antileukemia activity of early recovering NK cells after induction chemotherapy and HLA-identical stem cell transplantation in myeloid leukemias. Leukemia 20 (2006) 1632-1633
10. Niederwieser D., Gastl G., Rumpold H., Marth C., Kraft D., and Huber C. Rapid reappearance of large granular lymphocytes (LGL) with concomitant reconstitution of natural killer (NK) activity after human bone marrow transplantation (BMT). Br J Haematol 65 (1987) 301-305
11. Ruggeri L., Mancusi A., Burchielli E., Aversa F., Martelli M.F., and Velardi A. Natural killer cell alloreactivity in allogeneic hematopoietic transplantation. Curr Opin Oncol 19 (2007) 142-147
12. Olerup O., and Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 39 (1992) 225-235
13. Schaffer M., Aldener-Cannava A., Remberger M., Ringden O., and Olerup O. Roles of HLA-B, HLA-C and HLA-DPA1 incompatibilities in the outcome of unrelated stem-cell transplantation. Tissue Antigens 62 (2003) 243-250
14. Remberger M., Svahn B.M., Mattsson J., and Ringden O. Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation 78 (2004) 122-127
15. Remberger M., Svahn B.M., Hentschke P., Lofgren C., and Ringden O. Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant 24 (1999) 823-830
16. Storb R., Deeg H.J., Pepe M., et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 73 (1989) 1729-1734
17. Ringden O., Horowitz M.M., Sondel P., et al. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia?. Blood 81 (1993) 1094-1101
18. Ringden O., Remberger M., Persson U., et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 15 (1995) 619-625
19. Remberger M., Ringden O., Blau I.W., et al. No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood 98 (2001) 1739-1745
20. Hagglund H., Ringden O., Oman S., Remberger M., Carlens S., and Mattsson J. A prospective randomized trial of Filgrastim (r-metHuG-CSF) given at different times after unrelated bone marrow transplantation. Bone Marrow Transplant 24 (1999) 831-836
21. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus conference on acute GVHD Grading. Bone Marrow Transplant 15 (1995) 825-828
22. Ringden O. Management of graft-versus-host disease. Eur J Haematol 51 (1993) 1-12
23. Ringden O., Uzunel M., Rasmusson I., et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81 (2006) 1390-1397
24. Kaplan E., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
25. Gooley T.A., Leisenring W., Crowley J., and Storer B.E. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18 (1999) 695-706
26. Fine J., and Gray R. Proportional hazard model for the sub-distribution of competing risks. J Am Stat Assoc 94 (1999) 496-509
27. Barrett A.J., and Savani B.N. Does chemotherapy modify the immune surveillance of hematological malignancies?. Leukemia 23 (2009) 53-58
28. Ringden O., Barrett A.J., Zhang M.J., et al. Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses. Br J Haematol 121 (2003) 874-885
29. Remberger M., Ringden O., Ljungman P., et al. Booster marrow or blood cells for graft failure after allogeneic bone marrow transplantation. Bone Marrow Transplant 22 (1998) 73-78
30. Le Blanc K., Samuelsson H., Gustafsson B., et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 21 (2007) 1733-1738
31. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295 (2002) 2097-2100
32. Ringden O., Labopin M., Gorin N.C., et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 22 (2004) 416-423
33. Ringden O.T., Le Blanc K., and Remberger M. Granulocyte and granulocyte-macrophage colony-stimulating factors in allografts: uses, misuses, misconceptions, and future applications. Exp Hematol 33 (2005) 505-512